Navigation Links
Biopure Announces 2008 First Quarter Financial Results
Date:2/21/2008

CAMBRIDGE, Mass., Feb. 21 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced its financial results for the first fiscal quarter ended January 31, 2008. For the quarter, the company reported a net loss of $5.8 million, or $0.17 per common share, compared with a net loss of $6.9 million, or $0.53 per common share, for the corresponding period in 2007. Class A common shares outstanding on January 31, 2008 and 2007 were 34,971,087 and 15,543,025, respectively.

Revenues

Total revenues for the first fiscal quarter of 2008 were $573,000, including $419,000 from sales of the Company's veterinary product Oxyglobin(R), $58,000 from sales of Hemopure(R) in South Africa and $96,000 in research and development expense reimbursements from the U.S. government. Total revenues for the same period in fiscal 2007 were $594,000, including $444,000 from Oxyglobin sales, $16,000 from sales of Hemopure and $134,000 from government reimbursement. Payments from the government reimburse Biopure for trauma development expenses for Hemopure and vary with the amount of reimbursable activity for the government.

Oxyglobin revenues decreased during the first fiscal quarter of 2008 compared to 2007 because of a change in the arrangement between the Company and its European distributor. During the first quarter of fiscal 2007, the Company accounted for European sales on a consignment basis. Now the distributor buys product for its inventory upon shipment by the Company. The distributor did not purchase any inventory during the first fiscal quarter of 2008. This decrease was nearly offset by higher U.S. sales of Oxyglobin due to higher average selling prices. Hemopure sales increased during the first fiscal quarter of 2008 due
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Biopure Launches Updated Website
2. Biopure Announces Pricing of Equity Offering
3. Biopure Gives Update on Malaysia Joint Venture Discussions
4. PPD Announces Plan to Repurchase Shares of its Common Stock
5. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
6. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
7. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
8. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
9. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
10. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
11. 3SBio Inc. Announces Change to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , RICHMOND, Calif., Sept. 16 Sangamo BioSciences, ... Sangamo,s president and CEO, will provide an update on the progress ... company,s business strategy at 1:30 pm ET on Wednesday, September 23, ... held in New York City. , , The ...
... ANTONY, France, September 16 Stallergenes S.A.,has ... trial,(VO59.08) conducted in allergic rhinitis caused by birch pollen and,concerning ... of this pollen, rBet v 1. , ... recombinant allergen as an active,substance. To Stallergenes, knowledge, the use ...
... Sept. 16 /PRNewswire-Asia/ -- Fortis Healthcare, one of ... broaden inclusion,criteria for its upcoming diabetic foot clinical ... peripheral blood to treat critical limb ischemia,(diabetic foot). ... management, risk reduction and lengthy rehabilitation. The current,treatments ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference 2STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 2STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 3STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 4Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 2Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 3Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 4
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Apollo Robbins for the 2015 International CES debut ... Apollo Robbins will be at the NXT-ID ... some of his famous theft techniques to visiting media ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... WI, SEPTEMBER 7, 2010 The American Society of ... Soil Science Society of America (SSSA) will present the ... on Oct. 31-Nov. 3 in Long Beach, CA, ... , , The Hank Beachell Future Leader ...
... research on how genes affect responses to medicines, the National ... to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), ... is to use information about a patient,s genetic make-up to ... grown, so has PharmGKB. Begun in 2000 to catalog links ...
... St. Louis, MO Current research provides a novel ... LaBranche et al, "Characterization of the KRN cell transfer model ... the K/BxN mouse," appears in the September 2010 issue of ... of the population is affected by rheumatoid arthritis, and women ...
Cached Biology News:ASA, CSSA and SSSA present scholarships and fellowships 2ASA, CSSA and SSSA present scholarships and fellowships 3ASA, CSSA and SSSA present scholarships and fellowships 4ASA, CSSA and SSSA present scholarships and fellowships 5ASA, CSSA and SSSA present scholarships and fellowships 6ASA, CSSA and SSSA present scholarships and fellowships 7ASA, CSSA and SSSA present scholarships and fellowships 8ASA, CSSA and SSSA present scholarships and fellowships 9NIH expands key pharmacogenomics resource 2Casing the joint 2
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
... 71-18 mutS and ES1301 mutS are mismatch ... of these strains prevents repair of the ... high mutation efficiencies and making them helpful ... Altered Sites II Mutagenesis Systems. Both ES1301 ...
propidium iodide *1.0 mg/mL solution in water*...
Biology Products: